Mira Pharmaceuticals (Mira Pharmaceuticals) Cash-to-Debt : 3,529.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mira Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 3,529.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mira Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Mira Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

MIRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 9.59 Max: 3529
Current: 3529

During the past 3 years, Mira Pharmaceuticals's highest Cash to Debt Ratio was 3529.00. The lowest was 0.00. And the median was 9.59.

MIRA's Cash-to-Debt is ranked better than
93.72% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs MIRA: 3529.00

Mira Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Mira Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mira Pharmaceuticals Cash-to-Debt Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

9.59

0.72

920.60

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial					-	0.01	53.84	920.60	3,529.00

Competitive Comparison of Mira Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mira Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's Cash-to-Debt falls into.

Mira Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mira Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.603	/	(0.005	+	0)
	=	920.60

Mira Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.529	/	(0.001	+	0)
	=	3,529.00

Mira Pharmaceuticals (NAS:MIRA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mira Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

K6S:Germany

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.

Executives

Brian Patrick Mcnulty	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff	director	C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr	director, officer: Executive Chairman	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin	officer: Pres. & Chief Scientific Off.	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez	officer: CFO, Secretary & Treasurer	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll	director	100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov	director, officer: Chief Executive Officer	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173